[go: up one dir, main page]

CR9786A - Compuestos de bencimidazol-tiofeno - Google Patents

Compuestos de bencimidazol-tiofeno

Info

Publication number
CR9786A
CR9786A CR9786A CR9786A CR9786A CR 9786 A CR9786 A CR 9786A CR 9786 A CR9786 A CR 9786A CR 9786 A CR9786 A CR 9786A CR 9786 A CR9786 A CR 9786A
Authority
CR
Costa Rica
Prior art keywords
bencimidazol
compounds
thiophen
thiophen compounds
preparing
Prior art date
Application number
CR9786A
Other languages
English (en)
Inventor
Cheung Mui
Allen Mitte Kyle
Michael Salovich James
Original Assignee
Smithkline Beecham Corp
Fernando Quesada Quesada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Fernando Quesada Quesada filed Critical Smithkline Beecham Corp
Publication of CR9786A publication Critical patent/CR9786A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion proporciona compuestos de bencimidazol-tiofeno, composiciones farmaceuticas que los contienen, procedimientos para prepararlos y su uso como agentes farmaceuticos.
CR9786A 2005-09-06 2008-02-29 Compuestos de bencimidazol-tiofeno CR9786A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71433705P 2005-09-06 2005-09-06
US78624406P 2006-03-27 2006-03-27

Publications (1)

Publication Number Publication Date
CR9786A true CR9786A (es) 2008-05-22

Family

ID=37631488

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9786A CR9786A (es) 2005-09-06 2008-02-29 Compuestos de bencimidazol-tiofeno

Country Status (28)

Country Link
US (2) US7595330B2 (es)
EP (1) EP1937671B1 (es)
JP (1) JP5002597B2 (es)
KR (1) KR20080047585A (es)
AR (1) AR055616A1 (es)
AT (1) ATE452132T1 (es)
AU (1) AU2006287766B2 (es)
BR (1) BRPI0615668A2 (es)
CA (1) CA2621879A1 (es)
CR (1) CR9786A (es)
CY (1) CY1109916T1 (es)
DE (1) DE602006011192D1 (es)
DK (1) DK1937671T3 (es)
EA (1) EA014111B1 (es)
ES (1) ES2337929T3 (es)
HR (1) HRP20100122T1 (es)
IL (1) IL189897A0 (es)
JO (1) JO2578B1 (es)
MA (1) MA29816B1 (es)
MX (1) MX2008003173A (es)
NO (1) NO20081160L (es)
NZ (1) NZ566345A (es)
PE (1) PE20070518A1 (es)
PL (1) PL1937671T3 (es)
PT (1) PT1937671E (es)
SI (1) SI1937671T1 (es)
TW (1) TW200800967A (es)
WO (1) WO2007030361A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101495474A (zh) * 2006-05-23 2009-07-29 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的噻吩-甲酰胺类
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
WO2007143506A2 (en) * 2006-06-02 2007-12-13 Smithkline Beecham Corporation Substituted benzimidazole thiophene benzyl ether compounds
JP2009539770A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体
JPWO2008087736A1 (ja) * 2007-01-19 2010-05-06 宇部興産株式会社 アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
JP2010531887A (ja) * 2007-06-26 2010-09-30 グラクソスミスクライン エルエルシー ベンズイミダゾールチオフェンの調製方法
US8273890B2 (en) * 2007-06-29 2012-09-25 4Sc Ag Thiophene-imidazopyridines
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
WO2009151914A1 (en) * 2008-05-27 2009-12-17 Smithkline Beecham Corporation Methods for treating neoplasms with a combination of a plk inhibitor and retinoid
WO2009154645A1 (en) * 2008-06-20 2009-12-23 Smithkline Beecham Corporation Methods for the treatment of central nervous system tumors
CA2745596A1 (en) * 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
HUE035059T2 (hu) 2009-11-05 2018-05-02 Rhizen Pharmaceuticals S A Új benzopirán-kinát modulátorok
ES2710874T3 (es) 2011-05-04 2019-04-29 Rhizen Pharmaceuticals S A Compuestos novedosos como moduladores de proteína cinasas
SMT201900334T1 (it) 2012-07-04 2019-07-11 Rhizen Pharmaceuticals S A Inibitori selettivi di pi3k delta
KR102574152B1 (ko) * 2020-03-27 2023-09-05 (주) 업테라 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR102337029B1 (ko) 2020-03-27 2021-12-09 (주) 업테라 Plk1 선택적 분해 유도 화합물
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU760020B2 (en) 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
BR0313160A (pt) * 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
AU2003903440A0 (en) * 2003-07-04 2003-07-17 James Hardie International Finance B.V. Rainscreen apparatus and method
US7465807B2 (en) * 2003-10-16 2008-12-16 Smithkline Beecham Corporation Process for preparing benzimidazole thiophenes
JP4721428B2 (ja) 2003-10-20 2011-07-13 日本精工株式会社 ステアリング装置
GB0402809D0 (en) 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
JP2009507022A (ja) * 2005-09-06 2009-02-19 スミスクライン ビーチャム コーポレーション ベンズイミダゾールチオフェン類の位置選択的調製方法
WO2007030359A1 (en) * 2005-09-06 2007-03-15 Smithkline Beecham Corporation Benzimidazole thiophene compounds as plk modulators
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007143506A2 (en) * 2006-06-02 2007-12-13 Smithkline Beecham Corporation Substituted benzimidazole thiophene benzyl ether compounds
JP2009539770A (ja) * 2006-06-02 2009-11-19 スミスクライン ビーチャム コーポレーション Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体

Also Published As

Publication number Publication date
MA29816B1 (fr) 2008-09-01
SI1937671T1 (sl) 2010-04-30
NZ566345A (en) 2010-04-30
PT1937671E (pt) 2010-03-12
CY1109916T1 (el) 2014-09-10
AU2006287766A1 (en) 2007-03-15
AR055616A1 (es) 2007-08-29
EA014111B1 (ru) 2010-10-29
EP1937671A2 (en) 2008-07-02
US7595330B2 (en) 2009-09-29
PE20070518A1 (es) 2007-06-12
KR20080047585A (ko) 2008-05-29
PL1937671T3 (pl) 2010-05-31
JP5002597B2 (ja) 2012-08-15
MX2008003173A (es) 2008-03-18
JP2009508816A (ja) 2009-03-05
EA200800546A1 (ru) 2008-08-29
ES2337929T3 (es) 2010-04-30
NO20081160L (no) 2008-05-29
TW200800967A (en) 2008-01-01
AU2006287766B2 (en) 2010-06-24
US20070270437A1 (en) 2007-11-22
WO2007030361A3 (en) 2007-05-31
US7786127B2 (en) 2010-08-31
JO2578B1 (en) 2011-02-27
IL189897A0 (en) 2008-08-07
BRPI0615668A2 (pt) 2011-05-24
HK1117504A1 (en) 2009-01-16
EP1937671B1 (en) 2009-12-16
CA2621879A1 (en) 2007-03-15
ATE452132T1 (de) 2010-01-15
DK1937671T3 (da) 2010-04-26
US20080214567A1 (en) 2008-09-04
WO2007030361A2 (en) 2007-03-15
DE602006011192D1 (de) 2010-01-28
HRP20100122T1 (hr) 2010-05-31

Similar Documents

Publication Publication Date Title
CR9786A (es) Compuestos de bencimidazol-tiofeno
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ECSP10010722A (es) Compuestos orgánicos
UY32659A (es) Pirazinilpirazoles
DOP2011000176A (es) Compuestos organicos
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
DOP2011000171A (es) Compuestos organico
ECSP077271A (es) Derivados de pirimidina
HN2009001178A (es) 4-fenilo-piano-3,5-diones, 4 fenilo- thiopirano-3,5-diones y ciclohexanetriones como herbicidas novedosos
ECSP077259A (es) Derivados de pirimidina
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP099760A (es) Compuestos 1,3-diona biciclicos herbicidamente activos
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
UY30304A1 (es) Moduladores de mglur5 i
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
UY30308A1 (es) Moduladores de mglur5 v
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
UY30306A1 (es) Moduladores de mglur5 iii
UY30307A1 (es) Moduladores de mglur5 vi
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
DOP2006000268A (es) Agentes antibacterianos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)